NASDAQ: EDSA - Edesa Biotech, Inc.

Rentabilidad a seis meses: -8.17%
Sector: Healthcare

Calendario de promoción Edesa Biotech, Inc.


Acerca de la empresa

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that is in Phase 2b clinical study to treat chronic allergic contact dermatitis.

Más detalles
The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

EBITDA -0.0028
EV/EBITDA -78.31
IPO date 2015-11-05
ISIN CA27966L1085
Industry Biotechnology
P/BV 43.06
P/S 550.86
Sector Health Care
Валюта usd
Валюта отчета usd
Выручка 0.000411
Сайт https://www.edesabiotech.com
Цена ао 4.12
Число акций ао 0.02001 млрд
Cambio de precio por día: -8.76% (4.68)
Cambio de precio por semana.: -1.39% (4.33)
Cambio de precio por mes: -0.9281% (4.31)
Cambio de precio en 3 meses.: -0.6214% (4.2967)
Cambio de precio en seis meses: -8.17% (4.65)
Cambio de precio por año: -86.06% (30.625)
Cambio de precio en 3 años.: -50.58% (8.64)
Cambio de precio en 5 años.: +17.31% (3.64)
Cambio de precio desde principios de año.: +7.83% (3.96)

Subestimación

Nombre Significado Calificación
P/S 0 0
P/BV 2.41 6
P/E 0 0
EV/EBITDA -1.27 0
Total: 3.25

Eficiencia

Nombre Significado Calificación
ROA, % -94.2 0
ROE, % -118.81 0
Total: 0

Dividendos

Nombre Significado Calificación
Div yield, % 0 0
DSI 0 0
Total: 0

Deber

Nombre Significado Calificación
Debt/EBITDA -0.0102 10
Total: 9.8

Impulso de crecimiento

Nombre Significado Calificación
Rentabilidad Revenue, % 44.12 6
Rentabilidad Ebitda, % 229.38 10
Rentabilidad EPS, % 442.15 10
Total: 8.2



Supervisor Título profesional Pago año de nacimiento
Dr. Pardeep Nijhawan FRCPC, M.D. CEO, Company Secretary & Director 475.33k 1971 (53 año)
Dr. Michael J. Brooks M.B.A., Ph.D. President 439.27k 1978 (46 años)
Mr. Stephen L. Lemieux BA, CPA, CA, CPA, MMPA Chief Financial Officer 402.86k 1977 (47 años)

DIRECCIÓN: Canada, Markham. ON LR H, 100 Spy Court - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://www.edesabiotech.com